Alkem Laboratories Posts 11% Revenue Growth Amidst Profit Dip

Alkem Laboratories reported revenue from operations of INR 3,740 crore, an 11% increase year-on-year. India sales grew 10.3% to INR 2,497 crore, while international sales increased by 16% to INR 1,222 crore. The company's EBITDA margin stood at 20.5%. Net profit saw a degrowth of 21.7%, primarily due to consolidated tax adjustments.

Reader Takeaway: Healthy revenue growth offset by tax impact; monitor regulatory and CDMO progress.

What just happened

Alkem Laboratories announced its financial results, showcasing an 11% year-on-year increase in revenue to INR 3,740 crore. This growth was supported by robust performance in both its domestic and international markets. India sales reached INR 2,497 crore (up 10.3% YoY), and international sales contributed INR 1,222 crore (up 16% YoY). Despite the revenue surge, the company's net profit declined by 21.7%, attributed mainly to consolidated tax adjustments.

Why this matters

The revenue growth indicates strong market acceptance and expansion for Alkem's products. The outperformance in the Indian market against the IPM growth is a positive sign. However, the dip in net profit due to tax implications requires investor attention, as it impacts the bottom line. The regulatory update regarding the Daman facility, a key contributor to US revenue, also needs monitoring despite assurances of continued supplies.

The backstory

Alkem Laboratories is a significant player in the Indian pharmaceutical market, with a strong presence in both branded generics and generic drug segments. The company has been focusing on expanding its international footprint, particularly in the US market. Recent strategic moves include the acquisition of Occlutech and the development of its CDMO business through Enzene.

What changes now

The company will continue to integrate the recently acquired Occlutech, aiming for INR 400 crore in sales and breakeven EBITDA for the remaining fiscal year. The CDMO business, Enzene, is expected to reach a USD 30 million annualized revenue run-rate to break even by FY28. Management has guided a consolidated tax rate between 30%-32% for FY27.

Risks to watch

The Official Action Indicated (OAI) status at the Daman facility, despite no interruption in supplies, remains a critical watch point. The high operational expenses in the US CDMO business are currently impacting profitability, with breakeven anticipated in 4-5 quarters. Flat performance in the Trade Generics segment in Q1 due to strategic decisions also requires recovery in subsequent quarters.

Peer comparison

Alkem's India business grew at 13.2% compared to the IPM growth of 12.2%. The Acute segment grew 12.3% (vs IPM 10.1%), and the Chronic segment grew 17.9% (vs IPM 15.4%). This performance suggests Alkem is holding its ground or gaining market share in key therapeutic areas within India.

Context metrics (time-bound)

• Revenue from Operations: INR 3,740 crore (+11% YoY)
• India Sales: INR 2,497 crore (+10.3% YoY)
• International Sales: INR 1,222 crore (+16% YoY)
• EBITDA Margin: 20.5%
• Net Profit: -21.7% (Degrowth due to tax)

What to track next

Investors will be closely watching the resolution of the OAI status at the Daman facility and its long-term impact. Progress in the US CDMO business and the performance of the acquired Occlutech will be key metrics to track for future profitability and growth. Recovery in the Trade Generics segment is also crucial for sustained top-line momentum.